retatrutide patent ESC 2024: improves lipid and cardiovascular risk profile in Phase II trial 🌟 𝐆𝐋𝐏-𝐁𝐚𝐬𝐞𝐝 𝐏𝐞𝐩𝐭𝐢𝐝𝐞 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 &

I hope my friends in the compounding community call out this type of behavior and if I were one of the manufacturers of current approved GLP-1s (Novo Nordisk, Eli Lilly and Company, etc), I would explore legal action against any company who is blatantly abusing #drugshortage loopholes to engage in manufacturing and not #compounding

especially in cases of weight loss and associated volume loss in the face, neck and jawline

The Medicare GLP-1 Bridge starts July 1 with $50 weight loss drugs

Prader-Willi syndrome (PWS) is a genetic disorder characterized by short stature, low lean body mass, muscular hypotonia, mental retardation, behavioral abnormalities, dysmorphic features, and excessive appetite with progressive obesity

Documentation support for charts (shared decision note structure plus signature and receipt acknowledgement options)

Get personalised medical advice and start your journey.